Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Verrica Pharma submits NDA for molluscum contagiosum drug

Verrica Pharmaceuticals (NASDAQ:VRCA) submitted an NDA to the FDA for its molluscum contagiosum drug candidate, VP-102. Molluscum contagiosum is a viral skin infection that currently has no FDA-approved therapies. VP...

September 16, 2019

Developments

Wave Life Sciences gets FDA fast track designation for suvodirsen

Wave Life Sciences (NASDAQ:WVE) received FDA fast track designation for suvodirsen for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder caused by the absence of dystrophin – a protein that...

September 16, 2019

Developments

TG Therapeutics presents new data from Phase 2 and 3 trials of ublituximab

TG Therapeutics (NASDAQ:TGTX) presented initial Phase 3 and updated Phase 2 data for ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (RMS). At the 35th Annual...

September 13, 2019

Developments

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Akari Therapeutics (NASDAQ:AKTX) received FDA orphan drug designation for nomacopan for the treatment of bullous pemphigoid (BP). BP is a severe orphan inflammatory skin disease characterized by chronic blistering of...

September 13, 2019

Developments

Helius Medical adds new PoNS clinic in Quebec City

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is opening a new PoNS clinic in Quebec City, Canada to be operated by Clinique Cortex. The PoNS device is authorized in Canada for the acute treatment of chronic...

September 13, 2019

Developments

Tocagen fails Phase 3 trial in recurrent brain cancer

Tocagen’s (NASDAQ:TOCA) Phase 3 Toca 5 clinical trial, evaluating Toca 511 and Toca FC, in patients with recurrent high grade glioma, undergoing resection, missed the primary endpoint of overall survival, compared with...

September 12, 2019

Developments

INmune Bio receives USPTO allowance for DN-TNF-alpha platform

The U.S. Patent and Trademark Office (USPTO) gave INmune Bio (NASDAQ: INMB) notice of allowance for a patent, which covers the company’s INB03 program utilizing its dominant negative tumor necrosis factor–alpha (DN-TNF...

September 12, 2019

Developments

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

BeyondSpring (NASDAQ: BYSI) presented a poster of the design for its Phase 3 Study 103 at the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain on Sept. 9. Study 103 is a multi-center...

September 10, 2019

Developments

Zenabis to supply recreational cannabis to Ontario retail outlets

Zenabis Global (TSX:ZENA) inked a supply agreement with the Ontario Cannabis Retail Corp. (OCS) to supply adult-use recreational cannabis to retailers throughout the province. Zenabis will begin supplying OCS with 21...

September 10, 2019

Developments

Toronto Innovation Acceleration Partners in pact with Amgen

Toronto Innovation Acceleration Partners (TIAP), formerly MaRS Innovation, and Amgen (NASDAQ:AMGN) are collaborating to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member...

September 9, 2019

Verrica Pharma submits NDA for molluscum contagiosum drug

Wave Life Sciences gets FDA fast track designation for suvodirsen

TG Therapeutics presents new data from Phase 2 and 3 trials of ublituximab

Akari’s nomacopan gets FDA orphan drug designation for bullous pemphigoid

Helius Medical adds new PoNS clinic in Quebec City

Tocagen fails Phase 3 trial in recurrent brain cancer

INmune Bio receives USPTO allowance for DN-TNF-alpha platform

BeyondSpring presents Phase 3 NSCLC study design at world conference on lung cancer

Zenabis to supply recreational cannabis to Ontario retail outlets

Toronto Innovation Acceleration Partners in pact with Amgen

Follow Us

Subscribe

General

More

Subscribe